2013 - NANETS https://nanets.net/abstracts-archive/2013?format=html Thu, 15 Feb 2018 18:13:46 -0500 en-GB hourly 1 C16 – Neuroendocrine Tumors Arising in Meckel's Diverticula: Frequency of Advanced Disease Warrants Aggressive Management https://nanets.net/abstracts-archive/2013/247-c16-neuroendocrine-tumors-arising-in-meckel-s-diverticula-frequency-of-advanced-disease-warrants-aggressive-management?format=html C16 – Neuroendocrine Tumors Arising in Meckel's Diverticula: Frequency of Advanced Disease Warrants Aggressive Management Lorenzen

]]> https://nanets.net/abstracts-archive/2013/247-c16-neuroendocrine-tumors-arising-in-meckel-s-diverticula-frequency-of-advanced-disease-warrants-aggressive-management?format=html Lorenzen

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 18:13:46 -0500 C54 – The Immunohistochemical Expression of Islet 1 and PAX8 by Rectal Neuroendocrine Tumors Should be Taken into Account in the Differential Diagnosis of Metastatic Neuroendocrine Tumors of Unknown Primary Origin https://nanets.net/abstracts-archive/2013/285-c54-the-immunohistochemical-expression-of-islet-1-and-pax8-by-rectal-neuroendocrine-tumors-should-be-taken-into-account-in-the-differential-diagnosis-of-metastatic-neuroendocrine-tumors-of-unknown-primary-origin?format=html C54 – The Immunohistochemical Expression of Islet 1 and PAX8 by Rectal Neuroendocrine Tumors Should be Taken into Account in the Differential Diagnosis of Metastatic Neuroendocrine Tumors of Unknown Primary Origin Zhou

]]> https://nanets.net/abstracts-archive/2013/285-c54-the-immunohistochemical-expression-of-islet-1-and-pax8-by-rectal-neuroendocrine-tumors-should-be-taken-into-account-in-the-differential-diagnosis-of-metastatic-neuroendocrine-tumors-of-unknown-primary-origin?format=html Zhou

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:19 -0500 C52 – A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs https://nanets.net/abstracts-archive/2013/283-c52-a-multicenter-randomized-blinded-phase-3-study-of-pasireotide-lar-vs-octreotide-lar-in-patients-with-metastatic-neuroendocrine-tumors-net-with-disease-related-symptoms-inadequately-controlled-by-somatostatin-analogs?format=html C52 – A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs Wolin

]]> https://nanets.net/abstracts-archive/2013/283-c52-a-multicenter-randomized-blinded-phase-3-study-of-pasireotide-lar-vs-octreotide-lar-in-patients-with-metastatic-neuroendocrine-tumors-net-with-disease-related-symptoms-inadequately-controlled-by-somatostatin-analogs?format=html Wolin

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:18 -0500 C53 – Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study https://nanets.net/abstracts-archive/2013/284-c53-everolimus-plus-octreotide-long-acting-repeatable-lar-for-the-treatment-of-advanced-neuroendocrine-tumors-net-associated-with-carcinoid-syndrome-updated-overall-survival-results-from-radiant-2-study?format=html C53 – Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study Yao

]]> https://nanets.net/abstracts-archive/2013/284-c53-everolimus-plus-octreotide-long-acting-repeatable-lar-for-the-treatment-of-advanced-neuroendocrine-tumors-net-associated-with-carcinoid-syndrome-updated-overall-survival-results-from-radiant-2-study?format=html Yao

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:18 -0500 C51 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET) https://nanets.net/abstracts-archive/2013/282-c51-phase-1-expansion-study-of-an-oral-torc1-torc2-inhibitor-cc-223-in-non-pancreatic-neuroendocrine-tumors-net?format=html C51 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET) Wolin

]]> https://nanets.net/abstracts-archive/2013/282-c51-phase-1-expansion-study-of-an-oral-torc1-torc2-inhibitor-cc-223-in-non-pancreatic-neuroendocrine-tumors-net?format=html Wolin

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:17 -0500 C50 – The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors https://nanets.net/abstracts-archive/2013/281-c50-the-diamagnetic-effects-of-peritoneal-carcinomatosis-in-the-prognosis-of-patients-with-advanced-midgut-neuroendocrine-tumors?format=html C50 – The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors Wang

]]> https://nanets.net/abstracts-archive/2013/281-c50-the-diamagnetic-effects-of-peritoneal-carcinomatosis-in-the-prognosis-of-patients-with-advanced-midgut-neuroendocrine-tumors?format=html Wang

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:16 -0500 C49 – Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable? https://nanets.net/abstracts-archive/2013/280-c49-neuroendocrine-tumors-nets-of-unknown-primary-is-early-surgical-exploration-and-aggressive-debulking-justifiable?format=html C49 – Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable? Wang

]]> https://nanets.net/abstracts-archive/2013/280-c49-neuroendocrine-tumors-nets-of-unknown-primary-is-early-surgical-exploration-and-aggressive-debulking-justifiable?format=html Wang

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:15 -0500 C48 – 68Ga-DOTATATE PET/CT Imaging for Evaluation of Neuroendocrine Tumors (NET): The Vanderbilt Experience https://nanets.net/abstracts-archive/2013/279-c48-68ga-dotatate-pet-ct-imaging-for-evaluation-of-neuroendocrine-tumors-net-the-vanderbilt-experience?format=html C48 – 68Ga-DOTATATE PET/CT Imaging for Evaluation of Neuroendocrine Tumors (NET): The Vanderbilt Experience Walker

]]> https://nanets.net/abstracts-archive/2013/279-c48-68ga-dotatate-pet-ct-imaging-for-evaluation-of-neuroendocrine-tumors-net-the-vanderbilt-experience?format=html Walker

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:14 -0500 C47 – Metastatic Recurrent Small Bowel "Carcinoid": The Role of Blood Neuroendocrine Transcript Analysis in Diagnosis and Management https://nanets.net/abstracts-archive/2013/278-c47-metastatic-recurrent-small-bowel-carcinoid-the-role-of-blood-neuroendocrine-transcript-analysis-in-diagnosis-and-management?format=html C47 – Metastatic Recurrent Small Bowel "Carcinoid": The Role of Blood Neuroendocrine Transcript Analysis in Diagnosis and Management Teixeira

]]> https://nanets.net/abstracts-archive/2013/278-c47-metastatic-recurrent-small-bowel-carcinoid-the-role-of-blood-neuroendocrine-transcript-analysis-in-diagnosis-and-management?format=html Teixeira

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:13 -0500 C45 – Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney https://nanets.net/abstracts-archive/2013/276-c45-exploratory-analysis-of-early-response-signals-using-targeted-therapies-for-the-treatment-of-advanced-carcinoid-tumor-of-the-kidney?format=html C45 – Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney Subbiah

]]> https://nanets.net/abstracts-archive/2013/276-c45-exploratory-analysis-of-early-response-signals-using-targeted-therapies-for-the-treatment-of-advanced-carcinoid-tumor-of-the-kidney?format=html Subbiah

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:12 -0500 C46 – A Multicenter Phase II Trial Evaluating Safety and Efficacy of Activity Escalation with 177Lu-DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors, Based on Detailed Dosimetry and Patient Selection https://nanets.net/abstracts-archive/2013/277-c46-a-multicenter-phase-ii-trial-evaluating-safety-and-efficacy-of-activity-escalation-with-177lu-dota-tate-in-patients-with-disseminated-neuroendocrine-tumors-based-on-detailed-dosimetry-and-patient-selection?format=html C46 – A Multicenter Phase II Trial Evaluating Safety and Efficacy of Activity Escalation with 177Lu-DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors, Based on Detailed Dosimetry and Patient Selection Sundlov

]]> https://nanets.net/abstracts-archive/2013/277-c46-a-multicenter-phase-ii-trial-evaluating-safety-and-efficacy-of-activity-escalation-with-177lu-dota-tate-in-patients-with-disseminated-neuroendocrine-tumors-based-on-detailed-dosimetry-and-patient-selection?format=html Sundlov

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:12 -0500 C44 – Dosing Patterns for Octreotide LAR in Neuroendocrine Tumor (NET) Patients: NCCN NET Outcomes Database https://nanets.net/abstracts-archive/2013/275-c44-dosing-patterns-for-octreotide-lar-in-neuroendocrine-tumor-net-patients-nccn-net-outcomes-database?format=html C44 – Dosing Patterns for Octreotide LAR in Neuroendocrine Tumor (NET) Patients: NCCN NET Outcomes Database Strosberg

]]> https://nanets.net/abstracts-archive/2013/275-c44-dosing-patterns-for-octreotide-lar-in-neuroendocrine-tumor-net-patients-nccn-net-outcomes-database?format=html Strosberg

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:11 -0500 C43 – Increased Incidence of Second Malignancy in Patients with Neuroendocrine Tumours (NETs) of the Ileum and Colon (MGC) https://nanets.net/abstracts-archive/2013/274-c43-increased-incidence-of-second-malignancy-in-patients-with-neuroendocrine-tumours-nets-of-the-ileum-and-colon-mgc?format=html C43 – Increased Incidence of Second Malignancy in Patients with Neuroendocrine Tumours (NETs) of the Ileum and Colon (MGC) Stronge

]]> https://nanets.net/abstracts-archive/2013/274-c43-increased-incidence-of-second-malignancy-in-patients-with-neuroendocrine-tumours-nets-of-the-ileum-and-colon-mgc?format=html Stronge

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:10 -0500 C42 – Capecitabine Plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Tumors (NETs): An Italian Multicenter Retrospective Analysis https://nanets.net/abstracts-archive/2013/273-c42-capecitabine-plus-temozolomide-cap-tem-in-patients-with-advanced-neuroendocrine-tumors-nets-an-italian-multicenter-retrospective-analysis?format=html C42 – Capecitabine Plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Tumors (NETs): An Italian Multicenter Retrospective Analysis Spada

]]> https://nanets.net/abstracts-archive/2013/273-c42-capecitabine-plus-temozolomide-cap-tem-in-patients-with-advanced-neuroendocrine-tumors-nets-an-italian-multicenter-retrospective-analysis?format=html Spada

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:09 -0500 C40 – Von Recklinghausen's Disease and Pheochromocytoma: A Ten-Year Experience https://nanets.net/abstracts-archive/2013/271-c40-von-recklinghausen-s-disease-and-pheochromocytoma-a-ten-year-experience?format=html C40 – Von Recklinghausen's Disease and Pheochromocytoma: A Ten-Year Experience Shinall

]]> https://nanets.net/abstracts-archive/2013/271-c40-von-recklinghausen-s-disease-and-pheochromocytoma-a-ten-year-experience?format=html Shinall

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:08 -0500 C41 – Retrospective Review of Patients with Metastatic High Grade Neuroendocrine Carcinoma of the Pancreas: Memorial Sloan-Kettering Cancer Center Experience (MSKCC) https://nanets.net/abstracts-archive/2013/272-c41-retrospective-review-of-patients-with-metastatic-high-grade-neuroendocrine-carcinoma-of-the-pancreas-memorial-sloan-kettering-cancer-center-experience-mskcc?format=html C41 – Retrospective Review of Patients with Metastatic High Grade Neuroendocrine Carcinoma of the Pancreas: Memorial Sloan-Kettering Cancer Center Experience (MSKCC) Shum

]]> https://nanets.net/abstracts-archive/2013/272-c41-retrospective-review-of-patients-with-metastatic-high-grade-neuroendocrine-carcinoma-of-the-pancreas-memorial-sloan-kettering-cancer-center-experience-mskcc?format=html Shum

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:08 -0500 C39 – Tumor Heterogeneity in Small Intestine Neuroendocrine Tumors Metastatic to the Liver https://nanets.net/abstracts-archive/2013/270-c39-tumor-heterogeneity-in-small-intestine-neuroendocrine-tumors-metastatic-to-the-liver?format=html C39 – Tumor Heterogeneity in Small Intestine Neuroendocrine Tumors Metastatic to the Liver Shi

]]> https://nanets.net/abstracts-archive/2013/270-c39-tumor-heterogeneity-in-small-intestine-neuroendocrine-tumors-metastatic-to-the-liver?format=html Shi

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:07 -0500 C38 – Is Renal Toxicity From Y-90 DOTATOC Dependent Upon Dose per PRRT Treatment? https://nanets.net/abstracts-archive/2013/269-c38-is-renal-toxicity-from-y-90-dotatoc-dependent-upon-dose-per-prrt-treatment?format=html C38 – Is Renal Toxicity From Y-90 DOTATOC Dependent Upon Dose per PRRT Treatment? Sharma

]]> https://nanets.net/abstracts-archive/2013/269-c38-is-renal-toxicity-from-y-90-dotatoc-dependent-upon-dose-per-prrt-treatment?format=html Sharma

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:06 -0500 C37 – Systemic Toxicity after Delayed Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2013/268-c37-systemic-toxicity-after-delayed-peptide-receptor-radionuclide-therapy-in-patients-with-metastatic-neuroendocrine-tumors?format=html C37 – Systemic Toxicity after Delayed Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Tumors Riff

]]> https://nanets.net/abstracts-archive/2013/268-c37-systemic-toxicity-after-delayed-peptide-receptor-radionuclide-therapy-in-patients-with-metastatic-neuroendocrine-tumors?format=html Riff

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:05 -0500 C35 – A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs) https://nanets.net/abstracts-archive/2013/266-c35-a-phase-ii-clinical-and-translational-study-of-mk-2206-in-patients-with-metastatic-neuroendocrine-tumors-nets?format=html C35 – A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs) Reidy

]]> https://nanets.net/abstracts-archive/2013/266-c35-a-phase-ii-clinical-and-translational-study-of-mk-2206-in-patients-with-metastatic-neuroendocrine-tumors-nets?format=html Reidy

]]> support@adgcommunications.com (Super User) 2013 Thu, 15 Feb 2018 13:14:04 -0500